Abstracts tagged "IgG4 Related Disease"

Abstract Number: 0128 • ACR Convergence 2022
Advantages of Alternate-Day Glucocorticoid Treatment Strategy for IgG4-Related Disease: A Preliminary Retrospective Study ID: 1287015
Sho Fukui¹, Takehiro Nakai², Satoshi Kawaai³, Yukihiko Ikeda², Masei Suda⁴, Atsushi Nomura⁵, Hiromichi Tamaki², Mitsumasa Kishimoto⁶, Sachiko Ohde⁷ and Masato Okada², ¹Kyorin University Hospital, Tokyo, Japan, ²St. Luke's International Hospital, Tokyo, Japan, ³St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, ⁴Suwa Central Hospital, Nagano, Japan, ⁵St. Luke's International Hospital, Nagareyama, Japan, ⁶Kyorin University School of Medicine, Yokohama, Japan, ⁷Center for Clinical Epidemiology, St.Luke's International University, Tokyo, Japan
Background/Purpose: Alternate-day glucocorticoid (GC) treatment is an effective treatment option that can reduce GC-associated adverse events in patients with rheumatoid arthritis and other autoimmune rheumatic…
Abstract Number: 0144 • ACR Convergence 2022
The Association of Hypocomplementemia with Organ Involvement and Serum IgG4 in IgG4-related Disease
Guy Katz¹, Amelia S. Cogan¹, Grace McMahon¹, Sebastian Perez-Espina¹, Ana Fernandes¹, Cory Perugino¹, Zachary Wallace¹, John Atkinson², Alfred Kim² and John Stone³, ¹Massachusetts General Hospital, Boston, MA, ²Washington University School of Medicine, St. Louis, MO, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic immune-mediated disease that can affect nearly every organ in the body. Hypocomplementemia is common in some patients with…
Abstract Number: 0147 • ACR Convergence 2022
Rituximab in IgG4-Related Diseae: An Open-Label Non-Randomized Observational Study
Jens Vikse¹, Oyvind Midtvedt², Oyvind Molberg³, Bjørg Tilde Svanes Fevang⁴, Oyvind Palm², Torhild Garen², Katrine Brække Norheim⁵, Gunnstein Bakland⁶, Marianne Wallenius⁷ and Anna-Maria Hoffmann-Vold², ¹University of Bergen, Stavanger, Norway, ²Oslo University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Nepal, ⁴Haukeland University Hospital, Bergen, Norway, ⁵Stavanger University Hospital, Stavanger, Norway, ⁶University Hospital of North-Norway, Tromsø, Norway, ⁷St. Olav University Hospital, Trondheim, Norway
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, heterogenous and potentially severe disease. An open-label trial demonstrated efficacy of rituximab (RTX) in IgG4-RD. Recently, four distinct…
Abstract Number: 0815 • ACR Convergence 2022
Hyper-IgG4 in Patients with Systemic Autoinflammatory Disease
Brianne Navetta-Modrov and QingPing Yao, Stony Brook University, Stony Brook, NY
Background/Purpose: Hyper-immunoglobulin G4 (IgG4) has been reported in various conditions including autoimmune disease, gastrointestinal disorders, lymphoproliferative/granulomatous diseases and solid tumors. IgG4-related disease is an immune-mediated…
Abstract Number: 1570 • ACR Convergence 2022
Memory CD4+T Cell Signature Is Associated with Unfavorable Prognosis in IgG4-related Disease: Risk Stratification by Machine-learning
Yuxue Nie¹, zheng liu¹, Wei Cao², Taisheng Li² and Wen Zhang³, ¹Department of Rheumatology, Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ²Department of Infectious Diseases, Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Peking Union Medical College Hospital, Beijing, China
Background/Purpose: IgG4-related disease (IgG4-RD) is a chronic immune-mediated disease with significant heterogeneity. A better understanding of the variance in the immune signature of IgG4-RD will…
Abstract Number: 1571 • ACR Convergence 2022
Coronary Arteritis and Periarteritis Secondary to IgG4-related Disease in a Large, Single-center Cohort
Guy Katz¹, sandeep hedgire¹, James Stone², Sebastian Perez-Espina¹, Ana Fernandes¹, Cory Perugino¹, Zachary Wallace¹ and John Stone³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Reading, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic autoimmune fibroinflammatory disease capable of affecting most organ systems. Large-vessel vasculitis is a well-described manifestation of the disease.…
Abstract Number: 1576 • ACR Convergence 2022
Clinical Presentation and Outcome of Patients with Chronic Abdominal Periaortitis
Umar Ghaffar¹, Hannah Langenfeld², Cynthia Crowson³, Tanaz Kermani⁴, Michelle Burke¹, Boyd Viers¹, Aaron Potretzke¹, Haraldur Bjarnason¹, Kenneth J. Warrington¹ and Matthew J. Koster¹, ¹Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Eyota, MN, ⁴University of California Los Angeles, West Hills, CA
Background/Purpose: To evaluate the presentation features and outcomes of patients with chronic abdominal periaortitis in a large referral cohort. Methods: Using a proprietary medical text…
Abstract Number: 1840 • ACR Convergence 2022
The 2019 ACR/EULAR Classification Criteria for IgG4-Related Disease Perform Lower Than Expected: Data from a Norwegian Cohort
Jens Vikse¹, Oyvind Midtvedt², Oyvind Molberg³, Bjørg Tilde Svanes Fevang⁴, Oyvind Palm², Torhild Garen², Katrine Brække Norheim⁵, Gunnstein Bakland⁶, Marianne Wallenius⁷ and Anna-Maria Hoffmann-Vold², ¹University of Bergen, Stavanger, Norway, ²Oslo University Hospital, Oslo, Norway, ³Oslo University Hospital, Oslo, Nepal, ⁴Haukeland University Hospital, Bergen, Norway, ⁵Stavanger University Hospital, Stavanger, Norway, ⁶University Hospital of North-Norway, Tromsø, Norway, ⁷St. Olav University Hospital, Trondheim, Norway
Background/Purpose: Milestones in the field of IgG4-related disease (IgG4-RD) include the 2011 Comprehensive Diagnostic Criteria (CDC), the 2019 ACR/EULAR classification criteria, and the recent identification…
Abstract Number: 0209 • ACR Convergence 2021
IgG4 Related Disease: Response to Immunosuppressive Therapy – A Single Centre Retrospective Study in the United Kingdom
Shirish Sangle¹, Neil Morton², Alina Casian², Louise Nel², Jennifer Hannah³ and David D'Cruz⁴, ¹Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom, ²Guys and St Thomas' NHS Trust, London, United Kingdom, ³Kings College Hospital, London, United Kingdom, ⁴Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
Background/Purpose: IgG4 related disease (IgG4-RD) is a rare immune-mediated condition, increasingly being recognised as a multi-organ disorder. It is a relatively new entity and the…
Abstract Number: 0621 • ACR Convergence 2021
Case Series of IgG4-related Disease in African American Patients at Two Large Academic Centers
Jonathan Thaler¹, Sunita Dia² and Florina Constantinescu², ¹MedStar Georgetown University Hospital, Washington, DC, ²Medstar Washington Hospital Center, Washington, DC
Background/Purpose: IgG4-related Disease (IgG4-rD) is a fibroinflammatory disease with highly variable manifestations that can be difficult to diagnose. Response to treatment with prednisone and/or rituximab…
Abstract Number: 1102 • ACR Convergence 2021
Comorbidities and Causes of Hospitalizations in a Cohort of IgG4-Related Disease Patients from a Single Center
David Faz-Muñoz, Eduardo Martin-Nares, Alejandra Hernández-Delgado and Gabriela Hernandez-Molina, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The frequency and types of comorbidities, causes of hospitalization, and the differences among clinical phenotypes in patients with IgG4-related disease (IgG4-RD) have not been…
Abstract Number: 1103 • ACR Convergence 2021
Disease Associations with Very High Serum IgG4 Concentrations: A Retrospective Multi-Center Study
Matthew Baker¹, Claire Cook², Xiaoqing Fu³, Cory Perugino³, John Stone⁴ and Zachary Wallace⁵, ¹Stanford University, Menlo Park, CA, ²Division of Rheumatology, Allergy, and Immunology, Mass General Hospital, Boston, MA, ³Massachusetts General Hospital, Boston, MA, ⁴Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA
Background/Purpose: Serum IgG4 concentrations are used as part of the evaluation for suspected IgG4-related disease (IgG4-RD), but the specificity of this test, especially at very…
Abstract Number: 1113 • ACR Convergence 2021
Validation of the 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease in a Latin American Cohort
Eduardo Martin-Nares¹, Gabriela Hernandez-Molina¹, Diego Baenas², Jesús Delgado-de la Mora³, Francisco Caeiro⁴, Pamela Wurmann Kiblisky⁵, Victor Pimentel-Quiroz⁶, Valery Ascuña Valdivia⁷, David Faz-Muñoz¹, Emanuel Saad⁸, Ernesto Cairoli⁹, Sergio Elgueta Pinochet¹⁰, Hugo Madariaga Charaja¹¹, Daniel Montante-Montes de Oca³, Jesica Gallo¹², Manuel Ugarte-Gil⁶, Oscar Neira¹³, Paula Burgos¹⁴ and Sergio Paira¹⁵, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Servicio de Reumatología, Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ³Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Servicio de Reumatología, Hospital Privado Universitario de Córdoba, Cordoba, Argentina, ⁵Departamento de Medicina, Hospital Clínico Universidad de Chile, Santiago, Chile, ⁶Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ⁷Uveitis and Inflammatory Eye Diseases Area, Instituto Oftalmosalud, Arequipa, Peru, ⁸Departamento de Clínica Médica, Hospital Privado Universitario de Córdoba, Córdoba, Argentina, ⁹Autoimmune Diseases Unit, Centro Asistencial del Sindicato Médico del Uruguay (CASMU) and Hospital Evangélico, Montevideo, Uruguay, ¹⁰Departamento de Medicina, Sección Reumatología, Hospital Clínico de la Universidad de Chile, Santiago, Chile, ¹¹Rheumatology Department, Hospital Essalud Yanahuara, Arequipa, Peru, ¹²Sección de Reumatología, Hospital Central de Reconquista, Reconquista, Argentina, ¹³Hospital del Salvador, Universidad de ChileSección Reumatología, Hospital del Salvador, Universidad de Chile, Santiago, Chile, ¹⁴Departamento de Inmunología Clínica y Reumatología, Pontificia Universidad Católica de Chile, Santiago, Chile, ¹⁵Sección de Reumatología, Hospital José María Cullen, Santa Fe, Argentina
Background/Purpose: The 2019 ACR/EULAR classification criteria (2019 AECC) for IgG4-related disease (IgG4-RD) have been validated in cohorts mainly composed of Caucasian and Asian patients. Its…
Abstract Number: 1879 • ACR Convergence 2021
Delayed Diagnosis of IgG4 Related Disease Is Associated with Worse Outcome: A Retrospective, Real-life Observational Study
Elisheva Pokroy-Shapira¹, Iftach Sagy², Katya Meridor³ and Yair Molad⁴, ¹Institute of Rheumatology, Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petach Tikva, Israel, ²Clinical Research Center, Soroka University Medical Center, Beer Sheva and Ben Gurion University of the Negev, DVIRA, Israel, ³Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ⁴Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel
Background/Purpose: The purpose of this study was to characterize clinical and pathological features as well as disease outcome of an Israeli incident cohort of patients…
Abstract Number: 1888 • ACR Convergence 2021
Usefulness of 2019 ACR/EULAR Classification Criteria (AECC) for IgG4-Related Disease Differs Between Clinical Phenotypes of IgG4-RD
Gözde Kübra Yardımcı¹, Bayram Farisogulları², Gizem Ayan¹, Levent Kilic¹, Sule Apraş Bilgen¹ and Omer Karadag³, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey, ³Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey
Background/Purpose: ACR/EULAR Classification criteria for IgG4-related disease (IgG4-RD) newly published [1]. On the other hand, four distinctive phenotypes of IgG4-RD have been described [2]. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].